Metronomic Oral Vinorelbine in Patients With Metastatic Tumors

Phase 2

Completed

• Conditions: Breast Cancer; Non Small Cell Lung Cancer; Prostate Cancer
• Interventions: Drug: vinorelbine oral formulation

• Registration Number: NCT00278070
• Lead Sponsor: Hellenic Cooperative Oncology Group

Brief Summary

Patients with recurrent or metastatic solid tumors receive oral vinorelbine at one of three different doses (30 or 40 or 50 mg). Vinorelbine will be administered orally at a metronomic schedule three times a week: on Monday, Wednesday and Friday.

Detailed Description

The purpose of this study is to define the biologically optimal dose of vinorelbine when administered at a metronomic dosing schema. \[Metronomic chemotherapy refers to the close, regular administration of minimally toxic doses of cytotoxic drugs, with minimal or no drug-free breaks, over prolonged periods\]. Patients with recurrent or metastatic solid tumors are randomly assigned one of three different doses of oral vinorelbine (30 or 40 or 50 mg). Treatment is administered three times a week (Monday, Wednesday and Friday) continuously until disease progression or unacceptable toxicity or to a maximum of 24 months.

Study Timeline

• Study Start: 2006-01
• Study First Submitted: 2006-01-17
• Study First Submitted QC: 2006-01-17
• Study First Posted: 2006-01-18
• Status Verified: 2008-02
• Study Completion: 2008-02
• Last Update Submitted: 2008-02-27
• Last Update Posted: 2008-02-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Signed informed consent
• Ages 16 - 75 years
• Genders: both
• Performance status 0-2 according to the World Health Organization (WHO) scale
• Life expectancy of at least 16 weeks
• Adequate bone marrow, hepatic and renal functions
• Absence of brain metastasis
• Metastatic/locally advanced refractory prostate, breast or non-small cell lung cancer previously treated with no more than two chemotherapeutic regimens
• White blood cells >= 3500/mm^3
• Absolute neutrophil count >= 1500/mm^3
• Platelets >= 100,000/mm^3
• Total serum bilirubin less than 1.5 mg/dl
• Serum transaminases less than 2.0 x upper normal limit (UNL) unless attributed to liver metastases
• Serum creatinine within normal range

Exclusion Criteria

• Major active infection

• More than two prior chemotherapy regimens for metastatic disease

• Any of the following within the 12 months prior to starting the study treatment:

  • myocardial infarction,
  • severe/unstable angina,
  • coronary/peripheral artery bypass graft,
  • congestive heart failure,
  • cerebrovascular accident or transient ischemic attack, or pulmonary embolism,
  • cardiac dysrhythmias of grade >/= 2,
  • atrial fibrillation of any grade, or
  • heart rate corrected interval (QTc) > 450 msec for males or > 470 msec for females.

• Hypertension that cannot be controlled with medications (> 150/100 mmHg despite optimal medical therapy)

• Ongoing anti-coagulation therapy

• Pregnancy or breastfeeding

• Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration; or which, in the judgment of the investigator, would make the patient inappropriate for entry into the trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
3	vinorelbine oral formulation	-
1	vinorelbine oral formulation	-
2	vinorelbine oral formulation	-

Primary Outcome Measures

Name	Time	Method
time to treatment failure	TTF rates per arm will be compared at 4 and 6 months

Secondary Outcome Measures

Name	Time	Method
progression free survival	Patients will be assessed every 2 months during the first 6 months on treatment and every 4 months thereafter until documentation of objective tumor progression or death.
time to progression	Patients will be assessed every 2 months during the first 6 months on treatment and every 4 months thereafter until documentation of objective tumor progression.
toxicity	Acute toxicity will be assessed during the first 8 weeks, sub-acute 8 weeks to 4 months, chronic post 4 months
changes in blood concentrations of angiogenesis-associated surrogate markers and pharmacokinetics	Baseline values will be assessed for predictive potential and assessment on weeks 2,4,8, 12 and thereafter every 2 months they will be analyzed for their capacity to act as surrogate markers of treatment activity

Trial Locations

Locations (11)

Hygeia Hospital; 🇬🇷 Athens, Greece

Metropolitan Hospital; 🇬🇷 Athens, Greece

General Hospital of Chania; 🇬🇷 Chania, Greece

Sotiria Hospital; 🇬🇷 Athens, Greece

University General Hospital of Ioannina, Medical Oncology Dept; 🇬🇷 Ioannina, Greece

University Hospital of Patras; 🇬🇷 Patras, Greece

"Theagenio" Hospital; 🇬🇷 Thessaloniki, Greece

"Papageorgiou" Cancer Hospital; 🇬🇷 Thessaloniki, Greece

Henry Dunant Hospital; 🇬🇷 Athens, Greece

University Hospital "Attikon"; 🇬🇷 Athens, Greece

Agii Anargiri Cancer Hospital; 🇬🇷 Athens, Greece